Equillium (EQ) Retained Earnings (2017 - 2026)
Equillium (EQ) posted quarterly Retained Earnings of $370000.0 for Q1 2026, down 49.38% year-over-year from $731000.0 in Q1 2025, and up 1.93% quarter-over-quarter from $363000.0 in Q4 2025.
Equillium (EQ) Retained Earnings (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Retained Earnings for 10 consecutive years, with $370000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 49.38% year-over-year to $370000.0; the TTM figure through Mar 2026 stood at $370000.0 (down 49.38% YoY), while the FY2025 annual figure was $363000.0, up 100.19% from the prior year.
- Retained Earnings advanced to $370000.0 in Q1 2026 per EQ's latest filing, from $363000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $731000.0 in Q1 2025 and bottomed at -$212.4 million in Q3 2025.
- Historically, Retained Earnings has averaged -$77.0 million across 5 years, with a median of $76000.0 in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 392.42% — and 2023, when it sank 244494.74%.
- Equillium's Retained Earnings stood at $76000.0 in 2022, then tumbled by 244494.74% to -$185.7 million in 2023, then decreased by 4.34% to -$193.8 million in 2024, then jumped by 100.19% to $363000.0 in 2025, then climbed by 1.93% to $370000.0 in 2026.
- Business Quant data shows EQ's Retained Earnings at $370000.0 in Q1 2026, $363000.0 in Q4 2025, and -$212.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | -226.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -226.21 Mn |
| Mar 31, 2026 | 370,000.00 |
| Dec 31, 2025 | 363,000.00 |
| Sep 30, 2025 | -212.40 Mn |
| Jun 30, 2025 | -208.20 Mn |
| Mar 31, 2025 | 731,000.00 |
| Dec 31, 2024 | -193.81 Mn |
| Sep 30, 2024 | -188.01 Mn |
| Jun 30, 2024 | 251,000.00 |
| Mar 31, 2024 | 423,000.00 |
| Dec 31, 2023 | -185.74 Mn |
| Sep 30, 2023 | 458,000.00 |
| Jun 30, 2023 | 340,000.00 |
| Mar 31, 2023 | -176.35 Mn |
| Dec 31, 2022 | 76,000.00 |
| Sep 30, 2022 | 193,000.00 |
| Jun 30, 2022 | -149,000.00 |
| Mar 31, 2022 | -147.39 Mn |
| Dec 31, 2021 | -138,000.00 |
| Sep 30, 2021 | -66,000.00 |